216 related articles for article (PubMed ID: 28141765)
1. Role of cytokines and treatment algorithms in retinopathy of prematurity.
Hartnett ME
Curr Opin Ophthalmol; 2017 May; 28(3):282-288. PubMed ID: 28141765
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
6. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
8. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
9. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
[TBL] [Abstract][Full Text] [Related]
10. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
11. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
Patel JR; Ranjan SS; Wasserman BN
Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
[TBL] [Abstract][Full Text] [Related]
12. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
Chawla D; Darlow BA
Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
[TBL] [Abstract][Full Text] [Related]
13. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
Chow SC; Lam PY; Lam WC; Fung NSK
Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
[TBL] [Abstract][Full Text] [Related]
14. New trends in intravitreal anti-VEGF therapy for ROP.
Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
[TBL] [Abstract][Full Text] [Related]
15. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
16. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
Sauer L; Chandler M; Hartnett ME
Am J Ophthalmol; 2024 Apr; 260():190-199. PubMed ID: 38141904
[TBL] [Abstract][Full Text] [Related]
17. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
18. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
19. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
Sukgen EA; Atalay HT; Özdek Ş
Retina; 2022 Nov; 42(11):2194-2202. PubMed ID: 35962999
[TBL] [Abstract][Full Text] [Related]
20. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
